Actinium Pharmaceuticals (ATNM) Income from Non-Controlling Interests (2021 - 2022)
Actinium Pharmaceuticals (ATNM) posted quarterly Income from Non-Controlling Interests of $45000.0 for Q3 2022, down 80.69% year-over-year from $233000.0 in Q3 2021, and little changed quarter-over-quarter from $45000.0 in Q2 2022.
Actinium Pharmaceuticals (ATNM) Income from Non-Controlling Interests (2021 - 2022) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Income from Non-Controlling Interests for 2 consecutive years, with $45000.0 the latest figure, recorded in Q3 2022.
- In Q3 2022, Income from Non-Controlling Interests fell 80.69% year-over-year to $45000.0; the TTM figure through Dec 2022 stood at $1.0 million (down 9.97% YoY), while the FY2022 annual figure was $1.0 million, down 9.97% from the prior year.
- Income from Non-Controlling Interests held at $45000.0 in Q3 2022 per ATNM's latest filing, from $45000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $940000.0 in Q1 2022 and bottomed at $23000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 45,000.00 |
| Jun 30, 2022 | 45,000.00 |
| Mar 31, 2022 | 940,000.00 |
| Dec 31, 2021 | 23,000.00 |
| Sep 30, 2021 | 233,000.00 |
| Jun 30, 2021 | 266,000.00 |
| Mar 31, 2021 | 622,000.00 |